Organisms isolated from adults with cystic fibrosis

Annals of Clinical Microbiology and Antimicrobials

Volumn 3, Issue , 2004, Pages

  McManus, Terence E ^a   McDowell, Andrew ^a   Moore, John E ^a   Elborn, Stuart J ^a  

^a BELFAST CITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT;

ADULT; ARTICLE; BACTERIAL COUNT; BACTERIAL INFECTION; BACTERIUM ISOLATE; BACTERIUM ISOLATION; BURKHOLDERIA CEPACIA COMPLEX; CONTROLLED STUDY; CYSTIC FIBROSIS; FOLLOW UP; HAEMOPHILUS INFLUENZAE; HEALTH CARE FACILITY; HUMAN; MAJOR CLINICAL STUDY; NONHUMAN; PSEUDOMONAS AERUGINOSA; STATISTICAL SIGNIFICANCE; STENOTROPHOMONAS MALTOPHILIA; STREPTOCOCCUS PNEUMONIAE; SUPERINFECTION;

EID: 33750490780     PISSN: 14760711     EISSN: 14760711     Source Type: Journal    
DOI: 10.1186/1476-0711-3-26     Document Type: Article

References (19)

1. Govan JR, Nelson JW: Microbiology of lung infection in cystic fibrosis. Br Med Bull 1992, 48:912-930.
2. Ong EL, Ellis ME, Webb AK, Neal KR, Dodd M, Caul EO, Burgess S: Infective respiratory exacerbations in young adults with cystic fibrosis: role of viruses and atypical microorganisms. Thorax 1989, 44:739-742.
3. Rubio TT: Infection in patients with cystic fibrosis. Am J Med 1986, 81:73-77.
4. Armstrong D, Grimwood K, Carlin JB, Carzino R, Hull J, Olinsky A, Phelan PD: Severe viral respiratory infections in infants with cystic fibrosis. Pediatr Pulmonol 1998, 26:371-379.
5. Maselli JH, Sontag MK, Norris JM, MacKenzie T, Wagener JS, Accurso FJ: Risk factors for initial acquisition of Pseudomonas aeruginosa in children with csytic fibrosis identified by newborn screening. Pediatr Pulmonol 2003, 35:257-262.
6. Schaedel C, de MI, Hjelte L, Johannesson M, Kornfalt R, Lindblad A, Strandvik B, Wahlgren L, Holmberg L: Predictors of deterioration of lung function in cystic fibrosis. Pediatr Pulmonol 2002, 33:483-491.
7. Tablan OC, Chorba TL, Schidlow DV, White JW, Hardy KA, Gilligan PH, Morgan WM, Carson LA, Martone WJ, Jason JM,.: Psuedomonas cepacia colonization in patients with cystic fibrosis: risk factors and clinical outcome. J Pediatr 1985, 107:382-387.
8. Burns JL, Emerson J, Stapp JR, Yim DL, Krzewinski J, Louden L, Ramsey BW, Clausen CR: Microbiology of sputum from patients at cystic fibrosis centers in the United States. Clin Infect Dis 1998, 27:158-163.
9. Ledson MJ, Gallagher MJ, Jackson M, Hart CA, Walshaw MJ: Outcome of Burkholderia cepacia colonisation in an adult cystic fibrosis centre. Thorax 2002, 57:142-145.
10. Muhdi K, Edenborough FP, Gumery L, O'Hickey S, Smith EG, Smith DL, Stableforth DE: Outcome for patients colonised with Burkholderia cepacia in a Birmingham adult cystic fibrosis clinic and the end of an epidemic. Thorax 1996, 51:374-377.
11. Nixon GM, Armstrong DS, Carzino R, Carlin JB, Olinsky A, Robertson CF, Grimwood K: Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis. J Pediatr 2001, 138:699-704.
12. Rosentein BJ, Zeitlin PL: Prognosis in cystic fibrosis. Curr Opin Pulm Med 1995, 1:444-449.
13. Smyth A, Walters S: Prophylactic antibiotics for cystic fibrosis. Cochrane Database Syst Rev 2001:CD001912.
14. Sharma R, Florea VG, Bolger AP, Doehner W, Florea ND, Coats AJ, Hodson ME, Anker SD, Henein MY: Wasting as an independent predictor of mortality in patients with cystic fibrosis. Thorax 2001, 56:746-750.
15. Hendry J, Elborn JS, Nixon L, Shale DJ, Webb AK: Cystic fibrosis: inflammatory response to infection with Burkholderia cepacia and Psuedomonas aeruginosa. Eur Respir J 1999, 14:435-438.
16. Hughes JE, Stewart J, Barclay GR, Govan JR: Priming of neutrophil respiratory burst activity by lipopolysaccharide from Burkholderia cepacia. Infect Immun 1997, 65:4281-4287.
17. Hutchison ML, Poxton IR, Govan JR: Burkholderia cepacia produces a hemolysin that is capable of inducing apoptosis and degranulation of mammalian phagocytes. Infect Immun 1998, 66:2033-2039.
18. Dahl M, Nordestgaard BG, Lange P, Tybjaerg-Hansen A: Fifteen-year follow-up of pulmonary function in individuals heterozygous for the cystic fibrosis phenylalanine-508 deletion. J Allergy Clin Immunol 2001, 107:819-822.
19. Britto MT, Garrett JM, Dugliss MA, Daeschner CWJ, Johnson CA, Leigh MW, Majure JM, Schultz WH, Konrad TR: Risky behavior in teens with cystic fibrosis or sickle cell disease: a multicenter study. Pediatrics 1998, 101:250-256.